Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06883227 · ClinicalTrials.gov registry record
Investigating Health Impacts of Exposure to Harmful Algal Blooms
A clinical trial of Neurologic Disorder and Red Tide, sponsored by Roskamp Institute.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT06883227 is a study of Neurologic Disorder and Red Tide that is actively recruiting participants, run by Roskamp Institute. The registered enrollment target is 400 participants, below the 17,132-participant average among 12 other Neurologic Disorder trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06883227, a study of Neurologic Disorder and Red Tide, is actively recruiting participants, sponsored by Roskamp Institute.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
The goals of this project are to study the biological effects of environmental toxins (ET), in particular aquatic toxins such as brevetoxins (PbTx) and microcystin or their metabolites. This study is designed to examine the effects of the body from harmful algae blooms (HAB) as well as possibility of an association between exposure to the marine toxin, brevetoxin (PbTx), which is released from K. brevis during the red tide bloom, and the prevalence of neurological illnesses.
Conditions Studied
Study Locations (1)
Florida
- The Roskamp Institute - Sarasota
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-10-14 |
| Est. Completion | 2030-10-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06883227
The ClinicalTrials.gov registry entry for NCT06883227 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 17,132-participant average among 12 other Neurologic Disorder trials with a reported enrollment target (98% lower). The listed sponsor is Roskamp Institute, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Neurologic Disorder appearing as the primary indexed condition, and to 0 interventions.
NCT06883227 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06883227 about?
NCT06883227 is a clinical study titled "Investigating Health Impacts of Exposure to Harmful Algal Blooms". The goals of this project are to study the biological effects of environmental toxins (ET), in particular aquatic toxins such as brevetoxins (PbTx) and microcystin or their metabolites. This study is designed to examine the effects of the body from harmful algae blooms (HAB) as well as possibility o...
What is the current status of trial NCT06883227?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-10-14. Estimated completion is 2030-10-14.
What conditions does trial NCT06883227 study?
This clinical trial studies the following conditions: Neurologic Disorder, Red Tide, Florida.
Who is sponsoring clinical trial NCT06883227?
This trial is sponsored by Roskamp Institute, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06883227 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurologic Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Registry and Natural History of Epilepsy-Dyskinesia Syndromes
RECRUITING
-
The "What Is Important to Us" Communication Intervention Pilot Clinical Trial
RECRUITING · Phase 2
-
MS-ResearchBiomarkerS
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.